Corporate News Update – Silexion Therapeutics (SLXN)
Market Snapshot
- Price: $0.16 (as of 09:09 PM CET, Tuesday 20 Oct 2026)
- Volume (last 24 h): $779 600
- Market Capitalisation: $850 700
- Shares Outstanding: 5.6 million
- 24‑Hour Change: 0 % (flat)
- Year‑to‑Date Performance: –71.88 % since the end of the previous month
- 200‑Day Simple Moving Average: $7.62
- 52‑Week High: $35.60 (27 Oct 2025)
- 52‑Week Low: $0.14 (19 Oct 2026)
Recent Corporate Action
Silexion Therapeutics Corp has announced the postponement of its scheduled extraordinary general meeting (EGM) by one week, moving the date from 10 Oct 2026 to 17 Oct 2026. The meeting will focus on two shareholder proposals:
- Increase in Authorized Share Capital – to align the company with Nasdaq’s listing requirements.
- Reverse Share Split – aimed at restoring the required minimum bid price and improving liquidity.
Shareholders must submit proxies by the record date of 29 Sep 2026. Attendance will be available via webcast or telephone to accommodate a global investor base.
Clinical Programme Progress
Silexion’s RNA interference (RNAi) therapy targeting KRAS‑mutated pancreatic cancer has produced encouraging pre‑clinical data. These results add momentum to the company’s pipeline and place it within the rapidly expanding KRAS‑targeted therapy landscape, which has recently seen regulatory designations and late‑stage trials across multiple solid‑tumor indications.
Peer Performance – 24 Hours
| Company | Ticker | 24‑h Move | Current Price | Market Cap |
|---|---|---|---|---|
| Amiad Water | AMD.TA | 0 % | ILA 778.2 | ILA 76.7 mn |
| Hub Cyber Security | HUBC | –12.28 % | $0.34 | $716.5 k |
| Turbogen | TURB.TA | +3.66 % | ILA 1,112 | ILA 83.4 mn |
| My Size | MYSZ | –1.75 % | $1.05 | $983.8 k |
| Scisparc | SPRC | –17.65 % | $1.31 | $987.7 k |
Related Company Update – Neurotech International Limited (ASX: NTI)
Neurotech International Limited has reported significant progress in its pharmaceutical‑cannabinoid programme targeting neurodevelopmental disorders. The lead asset, NTI164, completed a Phase II/III double‑blind trial in children with autism spectrum disorder, demonstrating clinically meaningful improvements in adaptive and social functioning while maintaining a favourable safety profile. Regulatory milestones include FDA IND clearance and United States patent notices of allowance for methods of use in neuroinflammatory conditions. The company’s pipeline also encompasses programmes for cerebral palsy, Rett syndrome, and PANS/PANDAS, supported by pre‑clinical and early‑phase evidence. NTI’s strategy emphasizes a secure supply chain from cultivation to formulation and seeks strategic partnerships to expedite development and commercialization. Current financials reveal a modest cash position, supplemented by recent capital raises aimed at supporting the next phase of clinical activity.
This article synthesises publicly available data as of 20 Oct 2026 and is intended for informational purposes only. It does not constitute investment advice.